Dr Reddy’s Laboratories launches Lamotrigine tablets in US market

G Naga Sridhar Hyderabad | Updated on January 16, 2018


Pharma major Dr Reddy’s Laboratories has launched Lamotrigine Orally Disintegrating Tablets in the US market following an approval by the US Food & Drug Administration (USFDA).

The tablets are a therapeutic equivalent generic version of Lamictal ODT (lamotrigine) Orally Disintegrating Tablets of GSK group of companies. They are indicated in the treatment of certain types of seizures.

The Lamictal ODT brand and generic had US sales of approximately $65.5 million for the most recent 12 months ending in July 2016, according to IMS Health.

Dr Reddy’s scrip gained 0.80 per cent on the Bombay Stock Exchange on Monday to end at Rs 3,078.65.

Published on October 11, 2016

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor